OBJECTIVES• Evaluate the addition of trilaciclib to chemotherapy/checkpoint inhibitor
combination regimens through examination of various classes and schedules of …

Locally advanced squamous cell carcinoma of the head and neck (SCCHN) that is not
associated with human papillomavirus (HPV) has a poor prognosis in contrast to HPV …

Sarcomas are malignant tumors accounting for a high percentage of cancer morbidity and
mortality in children and young adults. Surgery and radiation therapy are the accepted …

Simple Summary This review provides an overview of the state of knowledge and general
understanding of CDK inhibitors currently under development or clinically approved, with a …

Introduction: Cyclin D-cyclin-dependent kinase (CDK) 4/6-inhibitor of CDK4/6-
retinoblastoma (Rb) pathway hyperactivation is associated with hormone receptor-positive …

Abstract The RB-E2F1 pathway is an important mechanism of cell-cycle control, and
deregulation of this pathway is one of the key factors contributing to tumorigenesis. Cyclin …

Simple Summary Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are widely used to
treat metastatic hormone receptor-positive/human epidermal growth factor receptor 2 …

Introduction We conducted a phase Ib study (NCT02345824) to determine whether
ribociclib, an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), penetrates tumor …

Objective Oesophageal squamous cell carcinoma (OSCC), like other squamous
carcinomas, harbour highly recurrent cell cycle pathway alterations, especially …

G1_ENA2018_Sorrentino_G1 Therapeutics Page 1 FIGURE 1. TRILACICLIB DOES NOT
DECREASE CHEMOTHERAPY EFFICACY IN CDK4/6-DEPENDENT CELL-BASED …